MHRA Outlines Submissions Process in Case of No-Deal Brexit

Drug Industry Daily
A A
In new guidance issued Monday, the UK’s Medicines and Health products Agency (MHRA) outlined how drugmakers and clinical trial sponsors can access the new MHRA gateway for UK submissions in case of a no-deal Brexit.

To View This Article:

Login

Subscribe To Drug Industry Daily